Makary says FDA will "end two-trial dogma" for approvals

FDA Commissioner Marty Makary and CBER director Vinay Prasad outline a policy shift to remove the default two-pivotal-trial requirement for new drug approvals, moving instead to allow a single robust pivotal trial supported by confirmatory evidence and synchronized with expanded post-market data collection. The proposal, published in the New England Journal of Medicine, is intended to accelerate drug development, lower costs and speed time-to-market (backed by a 2022 JAMA finding that >50% of 2020 approvals used a single pivotal trial), but it has drawn criticism over potential weakening of safety/efficacy standards and concerns about related initiatives such as the opaque CNPV expedited-review program and greater use of AI in agency decision-making.

Analysis

Market structure: Dropping the de facto two‑trial requirement favors large, diversified pharma (JNJ, PFE, MRK, BMY, ABBV) and CROs (IQV) because lower development time and cost lift NPV across big pipelines and increase demand for outsource services. Small cap clinical biotechs and specialty diagnostics lose bargaining power: less need for multiple confirmatory studies reduces their ability to extract premium valuations for de‑risked assets. Expect a re‑rating with ~5–15% relative outperformance of big pharm/CROs vs XBI/IBB over 6–12 months if implemented.

Risk assessment: Tail risk is regulatory backlash — Congressional hearings, litigation, or high‑profile post‑market safety events could force reversals and cause >30% drawdowns in exposed small caps within weeks. Immediate (days) volatility spikes on headlines; short‑term (weeks–months) uncertainty until formal FDA guidance; long term (quarters–years) the net depends on post‑market surveillance effectiveness and payor acceptance. Hidden dependency: faster approvals increase post‑market data needs, shifting costs from pre‑ to post‑approval and raising commercial/insurance/legal risk.

Trade implications: Direct plays: overweight large pharma and CROs, underweight early‑stage clinical biotech and small‑cap biotechs. Pair trade: long IQV (IQV) vs short XBI equal notional—expect CRO outperformance as filing cadence rises. Options: buy 6–9 month IQV bull call spreads and buy 3–6 month puts on concentrated small‑cap biotech holdings to hedge headline risk. Enter within 30–90 days around formal FDA guidance; scale on CNPV award announcements.

Key Decisions for Investors

• Establish a 2–3% long position in IQVIA (IQV) within 30 days, funded by reducing small‑cap biotech exposure; target +10–20% outperformance vs XBI over 6–12 months if FDA implements single‑trial standard.
• Add 1–2% long positions in large diversified pharmas (split between PFE and MRK) to capture faster approvals and cost savings; take profits on a 15–25% move or after formal FDA guidance publication within 60 days.
• Initiate a pair trade: long IQV (1.5%) vs short XBI (1.5%) equal notional; monitor relative performance weekly and widen shorts if XBI rallies >10% on headline euphoria.
• Buy a 6–9 month IQV bull call spread (debit) sized to 0.5–1% of portfolio and purchase 3–6 month puts on a basket/ETF of small‑cap biotech (e.g., XBI) sized to 1% to protect against a headline‑driven selloff.
• Reduce single‑name positions in clinical‑stage small biotechs (e.g., CRSP, BEAM if held) by 30–50% within 14 days unless they have at least one Phase III or strong confirmatory dataset; re‑deploy proceeds to CROs/large pharma or cash pending FDA guidance (monitor for guidance publication, CNPV award list, and any major post‑market safety recall within 90 days).